Ligilactobacillus salivarius explained

Ligilactobacillus salivarius is a probiotic bacteria species that has been found to live in the gastrointestinal tract and exert a range of therapeutic properties including suppression of pathogenic bacteria.[1]

Therapeutic research

Irritable bowel syndrome

Ligilactobacillus salivarius has been found to be of benefit in the alleviation of flatulence in individuals suffering from irritable bowel syndrome.[2]

Pancreatic necrosis

Pancreatic necrosis, if left untreated, has an almost 100 percent fatality rate due to bacterial translocation. Ligilactobacillus salivarius has been found to have a wide spectrum of coverage against pathogenic organisms that translocate from the gastrointestinal tract thereby demonstrating therapeutic benefit in the management of pancreatic necrosis. Research has shown that the addition of this species along with other probiotic species (specifically Bifidobacterium bifidum, Bifidobacterium infantis, Lactobacillus acidophilus, Lacticaseibacillus casei, and Lactococcus lactis) suppressed pro-inflammatory cytokines and further suppressed bacterial overgrowth in the small intestine leading to a reduction in bacterial translocation.[3]

Atopic dermatitis

Some studies have shown atopic dermatitis symptoms have been shown to be reversed in some children who given probiotics containing L. salivarius.[4] [5] [6]

Oral health

L. salivarius has been shown in some studies to improve periodontal health by reducing bleeding on probing and inhibiting harmful bacteria. While some strains may increase the risk of dental caries, others can decrease levels of Streptococcus mutans and enhance salivary buffering capacity, which may create a protective effect against dental caries and tooth decay. Additionally, L. salivarius may help manage halitosis by reducing bacteria associated with bad breath.

External links

Notes and References

  1. Neville . BA. . O'Toole . PW. . Probiotic properties of Lactobacillus salivarius and closely related Lactobacillus species. . Future Microbiol . 5 . 5 . 759–74 . May 2010 . 10.2217/fmb.10.35 . 20441548 .
  2. Ortiz-Lucas . M. . Tobías . A. . Saz . P. . Sebastián . JJ. . Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis. . Rev Esp Enferm Dig . 105 . 1 . 19–36 . Jan 2013 . 23548007 . 10.4321/s1130-01082013000100005. free .
  3. Ridwan . BU. . Koning . CJ. . Besselink . MG. . Timmerman . HM. . Brouwer . EC. . Verhoef . J. . Gooszen . HG. . Akkermans . LM. . Antimicrobial activity of a multispecies probiotic (Ecologic 641) against pathogens isolated from infected pancreatic necrosis. . Lett Appl Microbiol . 46 . 1 . 61–7 . Jan 2008 . 10.1111/j.1472-765X.2007.02260.x . 17944834 .
  4. Niccoli . A. A. . etal . Preliminary Results on Clinical Effects of Probiotic Lactobacillius Salivarius LS01 in Children Affected by Atopic Dermatitis . Journal of Clinical Gastroenterology . 48 . 48, supplement 1 . Nov–Dec 2014 . S34–6 . 10.1097/mcg.0000000000000233 . 25291124. free .
  5. Chaves BD, Brashears MM, Nightingale KK . Applications and safety considerations of Lactobacillus salivarius as a probiotic in animal and human health . Journal of Applied Microbiology . 123 . 1 . 18–28 . July 2017 . 28256040 . 10.1111/jam.13438.
  6. Guerrero Sanchez M, Passot S, Campoy S, Olivares M, Fonseca F . Ligilactobacillus salivarius functionalities, applications, and manufacturing challenges . Applied Microbiology and Biotechnology . 106 . 1 . 57–80 . January 2022 . 34889985 . 10.1007/s00253-021-11694-0.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Ligilactobacillus salivarius".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2025, A B Cryer, All Rights Reserved. Cookie policy.